Immunogenicity and efficacy comparison of MDCK cell-based and egg-based live attenuated influenza vaccines of H5 and H7 subtypes in ferrets

Yeolekar, Leena; Guilfoyle, Kate; Ganguly, Milan; Tyagi, Parikshit; Stittelaar, Koert J.; Amerongen, Geert van; Dhere, Rajeev; Berlanda-Scorza, Francesco; Mahmood, Kutub

doi:10.1016/j.vaccine.2020.07.043

Cited by 6 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seasonal influenza is a global public health threat, and vaccination is the most effective and dependable method for managing influenza epidemics (1). Madin-Darby canine kidney (MDCK) cells are susceptible to influenza virus infection and support virus replication; thus, they are used for cell-based influenza vaccines production (2). However, most inactivated or subunit influenza vaccines are poorly immunogenic and are ineffective at producing high levels of vaccinespecific serum antibodies in humans.…”

Section: Introductionmentioning

confidence: 99%

AddaVax Formulated with PolyI:C as a Potential Adjuvant of MDCK-based Influenza Vaccine Enhances Local, Cellular, and Antibody Protective Immune Response in Mice

et al. 2021

View full text Add to dashboard Cite

Poor immune responses to inactivated influenza vaccine can be improved by effective and safe adjuvants to increase antibody titers and cellular protective response. In our study, AddaVax and PolyI:C combined adjuvant (AP adjuvant) were used for influenza vaccine development. After immunizing BALB/c mice and Wistar rats intramuscularly, Split inactivated H3N2 vaccine adjuvanted with AP elicited higher serum hemagglutination-inhibition antibodies and IgG titers. We demonstrated that AP induced a transient innate immune cytokines production at the injection site, induced H3N2 uptake by DCs, increased recruitment of monocytes and DCs in LNs, and promoted H3N2 vaccine migration; AP facilitated vaccines to induce a vigorous adaptive immune response. Besides, AP showed good safety as shown by lymph nodes (LNs) size, spleens index of BALB/c mice, and weight changes and C-reaction protein level of BALB/c mice and Wistar rats after repeated administration of high-dose vaccine with or without adjuvant. These findings indicate that AP is a potential novel adjuvant and can be used as a safe and effective adjuvant for MDCK-based influenza inactivated vaccine to induce cellular and antibody protective response.

show abstract

Section: Introductionmentioning

confidence: 99%

AddaVax Formulated with PolyI:C as a Potential Adjuvant of MDCK-based Influenza Vaccine Enhances Local, Cellular, and Antibody Protective Immune Response in Mice

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Early studies using the ferret model showed that cellular immune responses, especially cytotoxicity T cells, play an important role in recovery from influenza virus infection [96,97]. Furthermore, several influenza vaccine platforms have been studied using ferret models [81][82][83]86,87,[98][99][100]. A study by Holzer et al described differential protective efficacy of the Signal Minus FLU vaccine candidate in ferrets and pigs [101].…”

Section: Pathogenesis and Transmissionmentioning

confidence: 99%

Animal Models for Influenza Research: Strengths and Weaknesses

Nguyen

Rollon

Choi

2021

Viruses

View full text Add to dashboard Cite

Influenza remains one of the most significant public health threats due to its ability to cause high morbidity and mortality worldwide. Although understanding of influenza viruses has greatly increased in recent years, shortcomings remain. Additionally, the continuous mutation of influenza viruses through genetic reassortment and selection of variants that escape host immune responses can render current influenza vaccines ineffective at controlling seasonal epidemics and potential pandemics. Thus, there is a knowledge gap in the understanding of influenza viruses and a corresponding need to develop novel universal vaccines and therapeutic treatments. Investigation of viral pathogenesis, transmission mechanisms, and efficacy of influenza vaccine candidates requires animal models that can recapitulate the disease. Furthermore, the choice of animal model for each research question is crucial in order for researchers to acquire a better knowledge of influenza viruses. Herein, we reviewed the advantages and limitations of each animal model—including mice, ferrets, guinea pigs, swine, felines, canines, and non-human primates—for elucidating influenza viral pathogenesis and transmission and for evaluating therapeutic agents and vaccine efficacy.

show abstract

“…The growth of egg-derived LAIV seeds in mammalian cells may also have the advantage of reducing the need for large numbers of SPF eggs which are difficult to source in many Asian countries, especially in the face of an influenza pandemic [56]. A full risk assessment and safety evaluation to qualify the cell line as suitable for use in man is required, as there is no inactivation step in LAIV production to treat adventitious agents.…”

Section: Cell Culture Vaccinesmentioning

confidence: 99%

New Technologies for Influenza Vaccines

Rockman

Laurie²,

Parkes³

et al. 2020

Microorganisms

View full text Add to dashboard Cite

Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vaccine development cycle. Critically, much of this progress has been leveraged off existing technologies, many of which had their beginnings in influenza vaccine development. This commentary outlines the most promising of the next generation of non-egg-based influenza vaccines including new manufacturing platforms, structure-based antigen design/computational biology, protein-based vaccines including recombinant technologies, nanoparticles, gene- and vector-based technologies, as well as an update on activities around a universal influenza vaccine.

show abstract

Immunogenicity and efficacy comparison of MDCK cell-based and egg-based live attenuated influenza vaccines of H5 and H7 subtypes in ferrets

Cited by 6 publications

References 21 publications

AddaVax Formulated with PolyI:C as a Potential Adjuvant of MDCK-based Influenza Vaccine Enhances Local, Cellular, and Antibody Protective Immune Response in Mice

AddaVax Formulated with PolyI:C as a Potential Adjuvant of MDCK-based Influenza Vaccine Enhances Local, Cellular, and Antibody Protective Immune Response in Mice

Animal Models for Influenza Research: Strengths and Weaknesses

New Technologies for Influenza Vaccines

Contact Info

Product

Resources

About